CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...